- Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood pressure)
- The company’s studies earlier this year indicated the potential of DehydraTECH to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation
- Arterial stiffness is a noted indicator of diseases such as heart, kidney and pancreas organ ailments that increase mortality with age, therefore the ability to reduce arterial stiffness may have implications for improving human wellness and longevity
- HYPER-H21-2 results evidence DehydraTECH-CBD reduces arterial stiffness
Lexaria Bioscience (NASDAQ: LEXX), an innovator in how drugs are utilized by the human body, is reporting newly found benefits from cannabidiol (“CBD”) enhanced by Lexaria’s patented DehydraTECH(TM) technology.
The company’s Dec. 8 news release notes that DehydraTECH-formulated CBD was found to reduce arterial stiffness in mild-to-moderate hypertension (high blood pressure) patients volunteering in Lexaria’s HYPER-H21-2 human clinical study (https://cnw.fm/zIrF2). The company believes the findings may have a potential impact on efforts to treat not only high blood pressure, but other cardiovascular diseases and other ailments in which blood vessel stiffness is believed to play a significant role.
“Reducing arterial stiffness in Lexaria’s recent hypertension study after only a single day of dosing with our DehydraTECH-CBD is a major discovery,” Lexaria President John Docherty stated in the news release. “We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people worldwide, and we are optimistic that our latest findings could have future widespread implications for promotion of improved human health and wellness.”
Lexaria’s examination of DehydraTECH-CBD’s effects on arterial stiffness follows its initial findings between July (https://cnw.fm/xLbY9) and September (https://cnw.fm/sK5Ak) that hypertensive volunteers using the company’s processed CBD achieved a marked drop in blood pressure relative to generic CBD controls used as a placebo.
DehydraTECH is an enabling technological solution that helps drug substances bypass the digestion-liver filtering cycle that may reduce their effectiveness. DehydraTECH’s platform works with the body to rapidly process drugs into the blood stream before potentially being filtered out by the liver’s enzyme-generating factory.
Additional testing by Canada’s premier federally funded research organization, the National Research Council demonstrated DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity (“NME”) and that each drug tested remained stable and did not undergo change in chemical structure. These findings are strongly supportive of accelerated regulatory filings such as the 505(b)(2) pathway permitted by the Food and Drug Administration and other international regulators, for more rapid market authorizations of prospective DehydraTECH-enabled, repurposed drugs (https://cnw.fm/abv6C).
Lexaria will follow the HYPER-H21-2 study with two new hypertension studies, HYPER-H21-3 and HYPER-H21-4, a new six-week investigation in which multiple doses of DehydraTECH-CBD are expected to indicate further benefits for treating hypertension and arterial stiffness.
Arterial stiffness naturally increases with age and is associated with increased mortality from diseases such as diabetes mellitus and kidney disorders, as well as the cardiovascular diseases that are the leading cause of death worldwide (https://cnw.fm/HY08k). Dr. Vernon V S Bonarjee, the head of the cardiology department at Norway’s Stavanger University Hospital, has noted that measuring arterial stiffness may serve as a predictive indicator for determining treatment for cardiovascular disease, even among otherwise asymptomatic individuals, demonstrating the condition’s significance (https://cnw.fm/AWuPQ).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About HempWire
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/Disclaimer
Do you have a questions or are you interested in working with HW? Ask our Editor
HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
HempWire is part of the InvestorBrandNetwork.
